<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology and natural history of mitral stenosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology and natural history of mitral stenosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology and natural history of mitral stenosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theo E Meyer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hemodynamic consequence of mitral stenosis (MS) is an increased impedance or resistance to transmitral flow. MS attenuates the atrial contribution to left ventricular filling and it also poses a hydraulic opposition or resistance to early filling. Unlike other valvular lesions, which are often attributable to many etiologies, MS alone, or in combination with other valvular pathology, is mostly secondary to rheumatic heart disease. However, the prevalence of calcific MS in resource-abundant countries has increased as populations age [<a href="#rid1">1</a>]. Progression of MS eventually leads to the development of disabling symptoms (eg, dyspnea, hemoptysis, thromboembolism, pulmonary hypertension, and right-sided heart failure). (See  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a>.)</p><p>The natural history and pathophysiology of MS will be reviewed here. Given the widespread use of surgical and percutaneous interventions, information on the natural history of MS comes from older studies and other limited observations of patients in resource-limited countries who have not undergone a corrective procedure.</p><p>The roles of medical and surgical therapy and the use of percutaneous balloon valvotomy are discussed separately. (See  <a class="medical medical_review" href="/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/8140.html" rel="external">"Surgical and investigational approaches to management of mitral stenosis"</a> and  <a class="medical medical_review" href="/d/html/8161.html" rel="external">"Percutaneous mitral balloon commissurotomy in adults"</a>.)</p><p class="headingAnchor" id="H436310590"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Rheumatic heart disease (RHD) is the most common cause of mitral stenosis (MS); other causes are much less frequent [<a href="#rid2">2,3</a>]. However, only 50 to 70 percent of patients with MS report a history of rheumatic fever [<a href="#rid4">4-6</a>]. RHD remains a major public health problem in resource-limited countries [<a href="#rid7">7-9</a>]. Rheumatic MS has become less common in resource-rich countries given marked reductions in the incidence of rheumatic fever [<a href="#rid10">10</a>]. Occasional outbreaks of rheumatic fever in the United States appear to be the result of either increased virulence of a streptococcal strain or immigration from areas where RHD is prevalent [<a href="#rid11">11</a>]. Involvement of the mitral valve is present in approximately 90 percent of individuals with RHD [<a href="#rid12">12</a>]. Since rheumatic MS is a chronic condition, it is not seen during the first episode of acute rheumatic carditis. In many populations, RHD is more common in females than in males [<a href="#rid9">9</a>]. Rheumatic MS is a continuously progressive lifelong disease. (See  <a class="medical medical_review" href="/d/html/3151.html" rel="external">"Acute rheumatic fever: Epidemiology and pathogenesis"</a>.)</p><p>The following are other causes of mitral stenosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Mitral annular calcification is a degenerative process of the fibrous support structure of the mitral valve. This form of MS is a common disorder, particularly in older adults, that may occasionally lead to hemodynamically significant MS [<a href="#rid1">1,13</a>]. (See  <a class="medical medical_review" href="/d/html/8122.html" rel="external">"Clinical manifestations and diagnosis of mitral annular calcification"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation-associated valve disease, including MS, is increasingly recognized as late manifestation in survivors of Hodgkin lymphoma that is associated with thickening and fibrosis of the aortic-mitral curtain [<a href="#rid14">14-16</a>]. These valve abnormalities may only be manifested 10 to 20 years after radiation treatment. Isolated MS is a rare complication from prior radiation. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital causes of MS are uncommon and usually present in infants and children [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other rare conditions include Fabry disease, Whipple disease, mucopolysaccharidosis, methysergide therapy, carcinoid valve disease, endomyocardial fibrosis, and systemic rheumatic disease (such as systemic lupus erythematosus and rheumatoid arthritis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions may produce hemodynamic abnormalities similar to those of native valvular MS; these include atrial myxoma, large infected vegetations, ball valve thrombus, and degenerated stenotic bioprosthetic mitral valve. (See  <a class="medical medical_review" href="/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management"</a>.)</p><p></p><p class="headingAnchor" id="H436311101"><span class="h1">PATHOPHYSIOLOGY</span></p><p>The nature and development of mitral stenosis (MS) should be considered in terms of the underlying etiology and pathology, the factors that contribute to progression, and the long-term hemodynamic and structural sequelae.</p><p class="headingAnchor" id="H13121386"><span class="h2">Pathoanatomic considerations</span></p><p class="headingAnchor" id="H13121426"><span class="h3">Rheumatic heart disease</span><span class="headingEndMark"> — </span>Rheumatic heart disease (RHD) is the result of an exaggerated immune response to specific bacterial epitopes in a susceptible host [<a href="#rid17">17</a>]. The inflammatory process in the valve leaflets is thought to be initiated by cross-reactivity between streptococcal antigen and the valve tissue; there is no evidence for active infection of the valve leaflets. Mitral disease begins with the formation of tiny nodules located along the coapting portions of the valve leaflets [<a href="#rid5">5</a>]. The leaflets thicken with eventual deposition of fibrin on the cusps and loss of normal valve morphology. Although the incidence of RHD is variable after an episode of acute rheumatic fever, approximately 50 percent of those with evidence of carditis develop organic valvular damage. In addition, up to 75 percent of patients with documented recurrences of rheumatic fever have some form of valvular disease after 45 years of follow-up  (<a class="graphic graphic_algorithm graphicRef104279" href="/d/graphic/104279.html" rel="external">algorithm 1</a>) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3151.html" rel="external">"Acute rheumatic fever: Epidemiology and pathogenesis"</a>.)</p><p>Chronic RHD affecting the mitral valve apparatus progresses over years to decades and causes a number of pathologic changes, affecting the mitral valve apparatus, which are diagnostic for rheumatic valve disease [<a href="#rid5">5,18</a>]: fusion of the leaflet commissures; thickening, fibrosis, and calcification of the leaflet cusps [<a href="#rid19">19</a>]; and thickening, fusion, and shortening of the chordae tendineae. The net effect is transition from a mitral valve that is often regurgitant early in the disease process to a stenotic mitral valve with a symmetric, central, oval-shaped orifice and a classic pattern of "doming" of the leaflets in diastole due to fusion of the leaflet tips at the commissures. The degree of leaflet thickening and calcification and the severity of chordal involvement are variable.</p><p>Commissural fusion and chordal shortening are due to recurrent rheumatic fever with repetitive valve scarring, but leaflet thickening and calcification appear to be primarily due to the stress of chronic turbulent flow through a deformed valve. Consistent with this hypothesis is the observation in a study from South Africa that ongoing rheumatic activity was present in 2 percent of patients with pure MS compared with 47 percent of patients with pure mitral regurgitation (MR) [<a href="#rid18">18</a>]. Also supportive of this hypothesis is the observation that recurrent stenosis after mitral valvuloplasty, without intervening episodes of rheumatic fever, is due to leaflet thickening and calcification without recurrent commissural fusion [<a href="#rid20">20-22</a>].</p><p>In some patients with MS the thickened, often calcified, mitral leaflets and chordae contribute to LV diastolic dysfunction. This is manifested by higher LV diastolic pressures and smaller diastolic volumes [<a href="#rid23">23</a>], and can be particularly prominent after balloon valvotomy.</p><p>Rheumatic MS has a delayed onset compared to rheumatic MR. The interval between the episode of rheumatic fever and the clinical presentation of MS varies geographically, ranging from as little as a few years in countries with a high prevalence of rheumatic fever [<a href="#rid18">18,24,25</a>] to 20 years in countries where rheumatic fever is rare [<a href="#rid3">3,5</a>]. Most children with RHD have pure MR (as illustrated by series in 12 African countries, India and Yemen [<a href="#rid9">9</a>], South Africa [<a href="#rid18">18</a>], Cameroon [<a href="#rid24">24</a>], and Mozambique [<a href="#rid26">26</a>]), with pure MS as well as mixed MS and MR increasing into adulthood [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease", section on 'Chronic valve disease'</a>.)</p><p>More rapid progression from MR to MS in areas of high prevalence may be due to the ineffective use of antibiotics and/or increased virulence of the Streptococcus organism causing a more severe primary rheumatic insult [<a href="#rid18">18,25</a>]. The ensuing acute inflammatory process can lead to commissural adhesion prior to the more common degenerative sequelae. It is therefore not uncommon in some of these countries to see symptomatic MS in patients less than 20 years of age [<a href="#rid9">9,18,24,25</a>], compared with the typical development of symptoms between the ages of 30 and 50 in developed nations [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H185053055"><span class="h3">Congenital MS</span><span class="headingEndMark"> — </span>Congenital MS is a rare condition that often involves multiple valve components, such as rolled, thickened leaflet margins, hypoplasia or fusion of the papillary muscles (including parachute mitral valve in which the mitral chordae are attached to a single or dominant papillary muscle [<a href="#rid28">28</a>]), and short and thickened chordae tendineae [<a href="#rid13">13,29,30</a>]. Parachute mitral valve is often a component of the Shone complex (which includes other left-sided obstructive lesions such as supramitral ring, valvular aortic stenosis, subaortic stenosis, and aortic coarctation). Atrioventricular canal defects are also associated with an increased risk of parachute mitral valve deformity. Accessory mitral valve tissue is a rare cause of congenital MS [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H185053129"><span class="h3">Mitral annular calcification</span><span class="headingEndMark"> — </span>Mitral annular calcification (MAC) develops from progressive calcium deposition along and beneath the mitral valve annulus. MAC generally follows the C-shape of the mitral annulus, so the base of the anterior mitral leaflet is generally (but not always) spared. Although data on the pathophysiology of MAC are very limited, an atherosclerotic process similar to that observed for calcific aortic valve disease has been proposed since atherosclerosis and MAC are strongly associated. Data have linked MAC to a decreased glomerular filtration rate, suggesting that associated abnormal calcium-phosphate metabolism is related to the pathogenesis of MAC [<a href="#rid32">32,33</a>].</p><p>Data have shown that MAC associated with severe calcific MS has a high burden of comorbidities. A study of 200 patients observed over a mean of 14 years demonstrated slow decrease in mean mitral valve area (by 0.05 cm<sup>2 </sup>per year) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/8122.html" rel="external">"Clinical manifestations and diagnosis of mitral annular calcification"</a>.)</p><p class="headingAnchor" id="H436311252"><span class="h2">Hemodynamic and structural sequelae</span></p><p class="headingAnchor" id="H13121913"><span class="h3">Altered filling dynamics</span><span class="headingEndMark"> — </span>The abnormal filling dynamics of MS are characterized by an increased transmitral pressure gradient. This diastolic pressure gradient is dependent on the severity of MS, cardiac output, and heart rate. In patients with mild to moderate MS, left atrial (LA) pressures are only minimally elevated at rest, but may increase to produce symptoms with exercise or other conditions that increase heart rate such as atrial fibrillation. In more severe forms of MS, LA pressures are usually significantly elevated at rest. The mean transmitral pressure gradient and the pulmonary venous pressure is increased in patients with MS when the cardiac output increases, as in anemic and pregnant patients  (<a class="graphic graphic_figure graphicRef104280" href="/d/graphic/104280.html" rel="external">figure 1</a>).</p><p>Progressive MS is associated with a gradual loss of cross-sectional valve area. The normal mitral valve orifice has a cross-sectional area of 4 to 6 cm<sup>2</sup>. In general, a valve area of &lt;2.5 cm<sup>2</sup> must be present before exertional dyspnea can be attributed to MS. A valve area of &lt;1.5 cm<sup>2</sup> is usually required to produce symptoms at rest  (<a class="graphic graphic_table graphicRef97546" href="/d/graphic/97546.html" rel="external">table 1</a>) [<a href="#rid34">34</a>]. An orifice area of ≤1.5 cm<sup>2</sup> is considered to represent severe MS, and is associated with a significant pressure gradient that is necessary to maintain adequate filling of the left ventricle. (See  <a class="medical medical_review" href="/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve"</a>.)</p><p>With isolated MS, the left ventricular systolic and diastolic pressures are usually normal. However, when the stenosis is very severe, there may be a decrease in left ventricular filling and end-diastolic volume (ie, preload), leading to reductions in stroke volume and cardiac output. Furthermore, the chronically elevated LA pressure leads to marked atrial remodeling and increased pulmonary venous as well as pulmonary arterial pressures and resistance  (<a class="graphic graphic_figure graphicRef104283" href="/d/graphic/104283.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization"</a>.)</p><p class="headingAnchor" id="H13121920"><span class="h3">Left atrial remodeling</span><span class="headingEndMark"> — </span>Chronic pressure overload leads to a range of adaptive processes in the LA, including myocardial hypertrophy, interstitial fibrosis, and geometric remodeling. These changes predispose to mechanical complications of LA chamber enlargement, in-situ thrombosis, and atrial fibrillation. An enlarged LA may impinge on the left recurrent laryngeal nerve, causing hoarseness (Ortner’s syndrome).</p><p>LA thrombosis is found in 17 to 24 percent of patients undergoing mitral valve surgery [<a href="#rid35">35,36</a>], and may be caused not only by stasis due to atrial fibrillation but also by endocardial injury secondary to chronic LA pressure overload. A scanning electronmicroscopy analysis of left and right atrial appendages of 35 patients who required corrective surgery for mitral valve disease showed that advanced changes were more frequently seen in the endocardium of the LA appendage compared with right atrial appendage [<a href="#rid37">37</a>]. Patients with MS had a higher proportion of advanced endocardial changes in the LA appendage compared with patients with MR. Further support for the concept that LA endothelial injury may be a mediator of LA thrombosis in MS independent of atrial fibrillation comes from a study in China that showed that the normalized expression of the von Willebrand factor gene relative to control was 3.04 in the LA appendage from 40 patients with LA thrombus and 2.16 in those without thrombosis (n = 40; p&lt;0.01) [<a href="#rid38">38</a>].</p><p>Other factors such as the shape of the LA may also predispose to an increased risk of LA thrombosis. Data suggest that at comparable volumes, a spherical LA shape had an increased risk for embolic cerebrovascular events compared with an elliptical-shaped LA [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H436311270"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Patients with MS commonly have pulmonary hypertension (PH), classified as PH due to left heart disease [<a href="#rid40">40</a>]. In most patients with PH caused by MS, the pulmonary artery pressure rises passively and maintains a normal or near-normal pulmonary arteriovenous pressure gradient. Likewise, the PA end-diastolic pressure minus the pulmonary venous pressure remains near zero. This subtype of increased pressures in the lung is also referred to as "postcapillary PH" [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"</a>.)</p><p>A minority of patients with MS and PH have "combined pre- and postcapillary PH" [<a href="#rid40">40</a>]. This type of reactive PH is due to vasoconstriction [<a href="#rid41">41</a>] and pathological remodeling of the pulmonary vasculature [<a href="#rid42">42</a>] and may be, in part, mediated by the potent vasoconstrictor endothelin-1 (ET-1). Levels of ET-1 are threefold higher in patients with severe MS compared with healthy control subjects [<a href="#rid43">43</a>]. In a group of patients with severe MS undergoing percutaneous balloon mitral valvuloplasty or mitral valve replacement, the baseline ET-1 concentration was an independent predictor of a decrease in pulmonary capillary wedge pressure at six months following mitral valve intervention [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Diagnostic criteria'</a>.)</p><p>The pulmonary vasculature remodels over time in patients with MS. There is progressive luminal narrowing due to intimal hyperplasia, enhanced proliferation and diminished apoptosis of endothelial and smooth-muscle cells, medial hypertrophy and fibrosis, and adventitial hypertrophy in small pulmonary arteries [<a href="#rid42">42</a>]. Changes are also evident in the small pulmonary veins, capillaries, and lymphatics. Veins may also exhibit thickened and fibrotic media and may be arterialized (ie, elastin fibers are condensed into internal and elastic laminae). The capillaries are often engorged, with thickened basement membranes and the lymphatics are dilated and thicker than normal. Pulmonary venous hypertension also leads to broncho-pulmonary anastomoses, which have been associated with hemoptysis. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Pathogenesis'</a>.)</p><p>Pulmonary arterial hypertension eventually leads to right ventricular hypertrophy and enlargement, tricuspid regurgitation, increased right atrial pressure, and the development of right-sided heart failure  (<a class="graphic graphic_figure graphicRef104283" href="/d/graphic/104283.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Right heart failure'</a>.)</p><p>Pulmonary hypertension in patients with MS is potentially reversible. This was illustrated in a randomized comparison of balloon valvuloplasty (valvotomy) and open surgical commissurotomy in patients with severe MS [<a href="#rid44">44</a>]. The mean pulmonary artery systolic pressure was approximately 55 mmHg at baseline and fell to 49 mmHg one week after the procedure and then to 32 mmHg at three-year follow-up  (<a class="graphic graphic_figure graphicRef73230" href="/d/graphic/73230.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H2"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>In the absence of correction of the stenotic lesion, rheumatic mitral stenosis (MS) is generally a progressive disease. Development of clinical evidence of progression is slow in asymptomatic patients but becomes more rapid after the onset of symptoms.</p><p>The number of patients with nonrheumatic MS is so small that little information is available concerning the natural history. (See  <a class="medical medical_review" href="/d/html/8122.html" rel="external">"Clinical manifestations and diagnosis of mitral annular calcification", section on 'Mitral stenosis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Rate of progression</span><span class="headingEndMark"> — </span>The mean rate of progressive valve narrowing is approximately 0.1 cm<sup>2</sup>/year in North American series, but there is appreciable interpatient variability [<a href="#rid45">45,46</a>]. This was illustrated in a Doppler echocardiographic evaluation of 103 patients with MS (mean age 61 years) [<a href="#rid45">45</a>]. During an average 3.3-year follow-up, mitral valve area decreased at a mean rate of 0.09 cm<sup>2</sup>/year but there was marked interpatient variability. There was no decrease in 28 patients, relatively little change (&lt;0.1 cm<sup>2</sup>/year) in 40, and more rapid (≥0.1 cm<sup>2</sup>/year) in 35. The rate of loss of valve area cannot be predicted by initial valve area [<a href="#rid45">45,46</a>].</p><p>In a study from Israel, investigators followed 36 patients with moderate MS for approximately six years [<a href="#rid47">47</a>]. The data suggest that the rate of mitral valve narrowing in patients with moderate MS is variable and cannot be predicted by patient's age, past commissurotomy, valve score, or gradient. Notably, in many patients, the valve area did not change over a long observation period.</p><p class="headingAnchor" id="H4"><span class="h2">Asymptomatic phase</span><span class="headingEndMark"> — </span>The duration of the asymptomatic phase (stage B and C)  (<a class="graphic graphic_table graphicRef97546" href="/d/graphic/97546.html" rel="external">table 1</a>) of rheumatic MS varies across geographical areas [<a href="#rid48">48</a>]. For example, in North America, it is generally a slowly progressive disease, with a latency period as long as 15 to 40 years between the initial infection and the onset of clinical symptoms [<a href="#rid3">3,4,13</a>]. In resource-limited settings, on the other hand, MS progresses much more rapidly, and may lead to symptoms in younger patients, typically in young adults, or in the teenage years, but even in children under five years of age in some countries [<a href="#rid49">49</a>].</p><p>The natural history of rheumatic MS was evaluated in a prospective study of 159 such patients from Germany [<a href="#rid3">3</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The mean interval between rheumatic fever and the onset of symptoms was 16.3 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At 25 years after the initial episode of rheumatic fever, 8 percent were asymptomatic, 9 percent were New York Heart Association (NYHA) class II, 33 percent were NYHA class III, and 50 percent were NYHA class IV or had undergone mitral valve surgery.</p><p></p><p>Similar findings were noted in an older report in which 49 asymptomatic patients were followed for 20 years: 24 percent remained asymptomatic, 14 percent developed symptoms or atrial fibrillation, and 62 percent died [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Symptomatic phase</span><span class="headingEndMark"> — </span>The prognosis dramatically worsens once the patient with MS develops symptoms (stage D)  (<a class="graphic graphic_table graphicRef97546" href="/d/graphic/97546.html" rel="external">table 1</a>). It has been estimated that progression from mild symptoms to severe disability takes only seven to nine years [<a href="#rid3">3,4</a>].</p><p>In the absence of correction of the stenosis, overall mortality increases as a patient's functional capacity decreases. This relationship can be illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study published in 1962, 271 symptomatic patients with MS were followed for up to 26 years after their initial presentation [<a href="#rid50">50</a>]. The 10-year survival rate for patients in functional class I, II, III, and IV was &gt;80, 69, 33, and 0 percent, respectively. At 20 years, 49 percent of patients in class II were still alive compared with no survivors among the patients in class III.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a later report, patients in whom valve surgery was recommended but refused had 5- and 10-year survival rates of 44 and 32 percent, respectively [<a href="#rid3">3</a>].</p><p></p><p>Other poor prognostic indicators include the presence of atrial fibrillation [<a href="#rid50">50</a>] and the progression to severe pulmonary hypertension [<a href="#rid51">51</a>]. In one series of 586 patients with mitral valve disease, 8.2 percent had severe pulmonary hypertension, defined as a resting systolic pulmonary artery pressure of 80 mmHg or above and pulmonary vascular resistance of 10 Woods units or greater [<a href="#rid51">51</a>]. The mean survival of patients with pulmonary hypertension who did not undergo surgery was 2.4 years [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Effect of pregnancy</span><span class="headingEndMark"> — </span>The increase in heart rate and cardiac output during pregnancy can substantially increase the resting transmitral gradient in females with MS, which can lead to symptoms in a previously asymptomatic (and perhaps undiagnosed) patient or an exacerbation of symptoms in an already symptomatic patient. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8133.html" rel="external">"Pregnancy in women with mitral stenosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Complications</span><span class="headingEndMark"> — </span>In addition to the gradual progression just described, as many as one-half of patients have one or more episodes of acute deterioration due to one of the complications of MS [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic or paroxysmal atrial fibrillation occurs in approximately 45 percent of cases, making it the most common cause of disability in a previously asymptomatic patient [<a href="#rid4">4-6</a>]. As mentioned above, a rapid ventricular rate raises left atrial and pulmonary venous pressures because of the reduction in diastolic filling time. Potential complications include pulmonary edema, hemoptysis, and pulmonary hemorrhage [<a href="#rid4">4,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to surgical correction and the use of prophylactic anticoagulation, systemic thromboembolic events complicated MS in 13 to 26 percent of patients [<a href="#rid4">4,6,52</a>]. The majority of events occurred in patients with atrial fibrillation, but some had no known history of this arrhythmia. Most of these emboli arose from the left atrium. Emboli can also arise from the right atrium, leading to pulmonary embolism, when there is pulmonary hypertension and right ventricular and atrial dilatation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MS and pulmonary hypertension may develop functional tricuspid regurgitation that often improves with successful treatment of the MS. The decrease in severity of tricuspid regurgitation parallels the decrease in pulmonary artery pressures. On rare occasions, rheumatic tricuspid stenosis and regurgitation are also found in patients with MS. (See  <a class="medical medical_review" href="/d/html/8119.html" rel="external">"Etiology, clinical features, and evaluation of tricuspid regurgitation"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Causes of death</span><span class="headingEndMark"> — </span>Death from MS is due to progressive right-sided heart failure and/or pulmonary edema in over 60 percent of cases [<a href="#rid6">6,50</a>]. Most of the remaining deaths are due to systemic thromboembolic events, 40 percent of which involve the brain, or a large pulmonary embolism [<a href="#rid53">53</a>]. In older studies, infectious complications, such as endocarditis, accounted for 5 to 8 percent of deaths [<a href="#rid6">6,50</a>]. However, the great majority of these fatal infectious complications occurred in the preantibiotic era.</p><p class="headingAnchor" id="H2183009476"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H18406856"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Mitral stenosis (MS) is due to thickening and immobility of the mitral valve leaflets  (<a class="graphic graphic_figure graphicRef79932" href="/d/graphic/79932.html" rel="external">figure 4</a>), resulting in obstruction in blood flow from the left atrium to the left ventricle. The mechanical obstruction leads to increases in pressure within the left atrium, pulmonary vasculature, and right heart. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cause</strong> – In nearly all cases, MS is caused by rheumatic involvement of the mitral valve. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatic MS</strong> – Disease progression results in a number of pathologic changes affecting the mitral valve apparatus, which are diagnostic for rheumatic valve disease: fusion of the leaflet commissures; and thickening, fusion, and shortening of the chordae tendineae. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rate of progression</strong> – In the absence of correction of the stenotic lesion, MS is generally a progressive disease. Progression is slow in asymptomatic patients but becomes more rapid after the onset of symptoms. The rate of progression of MS varies across geographical areas. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stages of MS</strong> – The stages of MS delineate the transition from an asymptomatic phase (stage B as and C) to a symptomatic phase (stage D)  (<a class="graphic graphic_table graphicRef97546" href="/d/graphic/97546.html" rel="external">table 1</a>). In general, a valve area of &lt;2.5 cm<sup>2</sup> must be present before exertional dyspnea can be attributed to MS; a valve area of &lt;1.5 cm<sup>2</sup> is usually required to produce symptoms at rest  (<a class="graphic graphic_table graphicRef97546" href="/d/graphic/97546.html" rel="external">table 1</a>). (See <a class="local">'Rate of progression'</a> above and  <a class="medical medical_review" href="/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve"</a> and  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Diagnosis and evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of atrial fibrillation</strong> – Atrial fibrillation is often the first trigger of symptoms in asymptomatic patients. (See <a class="local">'Altered filling dynamics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of pregnancy</strong> – The increase in heart rate and cardiac output during pregnancy can substantially increase the resting transmitral gradient in females with MS, which can lead to symptoms in a previously asymptomatic (and perhaps undiagnosed) patient or an exacerbation of symptoms in an already symptomatic patient. (See <a class="local">'Effect of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of MS include atrial fibrillation, systemic thromboembolic events, secondary pulmonary hypertension, tricuspid regurgitation, and heart failure. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of death</strong> – Death from MS is due to progressive right-sided heart failure and/or pulmonary edema in over 60 percent of cases. Most of the remaining deaths related to MS are due to systemic thromboembolic events. (See <a class="local">'Causes of death'</a> above.)</p><p></p><p class="headingAnchor" id="H14664818"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges William H Gaasch, MD (deceased), who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Matthew J Sorrentino, MD, FACC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kato N, Padang R, Scott CG, et al. The Natural History of Severe Calcific Mitral Stenosis. J Am Coll Cardiol 2020; 75:3048.</a></li><li><a class="nounderline abstract_t">Olson LJ, Subramanian R, Ackermann DM, et al. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc 1987; 62:22.</a></li><li><a class="nounderline abstract_t">Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J 1991; 12 Suppl B:55.</a></li><li><a class="nounderline abstract_t">WOOD P. An appreciation of mitral stenosis. I. Clinical features. Br Med J 1954; 1:1051.</a></li><li><a class="nounderline abstract_t">Selzer A, Cohn KE. Natural history of mitral stenosis: a review. Circulation 1972; 45:878.</a></li><li><a class="nounderline abstract_t">ROWE JC, BLAND EF, SPRAGUE HB, WHITE PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med 1960; 52:741.</a></li><li><a class="nounderline abstract_t">Rheumatic fever and rheumatic heart disease. World Health Organ Tech Rep Ser 2004; 923:1.</a></li><li><a class="nounderline abstract_t">Sani MU, Karaye KM, Borodo MM. Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study. Cardiovasc J Afr 2007; 18:295.</a></li><li><a class="nounderline abstract_t">Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015; 36:1115.</a></li><li><a class="nounderline abstract_t">Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 1985; 72:1155.</a></li><li><a class="nounderline abstract_t">Feldman T. Rheumatic mitral stenosis. On the rise again. Postgrad Med 1993; 93:93.</a></li><li><a class="nounderline abstract_t">BLAND EF, DUCKETT JONES T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation 1951; 4:836.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Adabag AS, Dykoski R, Ward H, Anand IS. Critical stenosis of aortic and mitral valves after mediastinal irradiation. Catheter Cardiovasc Interv 2004; 63:247.</a></li><li><a class="nounderline abstract_t">Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831.</a></li><li><a class="nounderline abstract_t">Brand MD, Abadi CA, Aurigemma GP, et al. Radiation-associated valvular heart disease in Hodgkin's disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 2001; 10:681.</a></li><li><a class="nounderline abstract_t">Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005; 366:155.</a></li><li><a class="nounderline abstract_t">Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med 1994; 120:177.</a></li><li><a class="nounderline abstract_t">Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005; 111:3296.</a></li><li><a class="nounderline abstract_t">Hernandez R, Bañuelos C, Alfonso F, et al. Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 1999; 99:1580.</a></li><li><a class="nounderline abstract_t">Wang A, Krasuski RA, Warner JJ, et al. Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy. J Am Coll Cardiol 2002; 39:328.</a></li><li><a class="nounderline abstract_t">Chen CR, Cheng TO. Percutaneous balloon mitral valvuloplasty by the Inoue technique: a multicenter study of 4832 patients in China. Am Heart J 1995; 129:1197.</a></li><li><a class="nounderline abstract_t">El Sabbagh A, Reddy YNV, Barros-Gomes S, et al. Low-Gradient Severe Mitral Stenosis: Hemodynamic Profiles, Clinical Characteristics, and Outcomes. J Am Heart Assoc 2019; 8:e010736.</a></li><li><a class="nounderline abstract_t">Tantchou Tchoumi JC, Butera G. Rheumatic valvulopathies occurence, pattern and follow-up in rural area: the experience of the Shisong Hospital, Cameroon. Bull Soc Pathol Exot 2009; 102:155.</a></li><li><a class="nounderline abstract_t">Tadele H, Mekonnen W, Tefera E. Rheumatic mitral stenosis in children: more accelerated course in sub-Saharan patients. BMC Cardiovasc Disord 2013; 13:95.</a></li><li><a class="nounderline abstract_t">Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357:470.</a></li><li><a class="nounderline abstract_t">Sliwa K, Carrington M, Mayosi BM, et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J 2010; 31:719.</a></li><li><a class="nounderline abstract_t">Hakim FA, Kendall CB, Alharthi M, et al. Parachute mitral valve in adults-a systematic overview. Echocardiography 2010; 27:581.</a></li><li><a class="nounderline abstract_t">Ruckman RN, Van Praagh R. Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications. Am J Cardiol 1978; 42:592.</a></li><li><a class="nounderline abstract_t">Moore P, Adatia I, Spevak PJ, et al. Severe congenital mitral stenosis in infants. Circulation 1994; 89:2099.</a></li><li><a class="nounderline abstract_t">Rao N, Gajjar T, Desai N. Accessory mitral valve tissue: an unusual cause of congenital mitral stenosis. Interact Cardiovasc Thorac Surg 2012; 14:110.</a></li><li><a class="nounderline abstract_t">Abd Alamir M, Radulescu V, Goyfman M, et al. Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: Results from CRIC study. Atherosclerosis 2015; 242:117.</a></li><li><a class="nounderline abstract_t">Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral Annulus Calcification. J Am Coll Cardiol 2015; 66:1934.</a></li><li><a class="nounderline abstract_t">HUGENHOLTZ PG, RYAN TJ, STEIN SW, ABELMANN WH. The spectrum of pure mitral stenosis. Hemodynamic studies in relation to clinical disability. Am J Cardiol 1962; 10:773.</a></li><li><a class="nounderline abstract_t">Shrestha NK, Moreno FL, Narciso FV, et al. Two-dimensional echocardiographic diagnosis of left-atrial thrombus in rheumatic heart disease. A clinicopathologic study. Circulation 1983; 67:341.</a></li><li><a class="nounderline abstract_t">Hao xh, Lai YQ, Li JH, et al. Analysis of risk factors for left atrial thrombosis in patients with rheumatic mitral stenosis. Chin J Thorac Cardio Surg 2011; 27:293.</a></li><li><a class="nounderline abstract_t">Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140:777.</a></li><li><a class="nounderline abstract_t">Luo ZQ, Hao XH, Li JH, et al. Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis. J Thorac Cardiovasc Surg 2014; 148:1970.</a></li><li><a class="nounderline abstract_t">Nunes MC, Handschumacher MD, Levine RA, et al. Role of LA shape in predicting embolic cerebrovascular events in mitral stenosis: mechanistic insights from 3D echocardiography. JACC Cardiovasc Imaging 2014; 7:453.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Mahoney PD, Loh E, Blitz LR, Herrmann HC. Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension. Am J Cardiol 2001; 87:188.</a></li><li><a class="nounderline abstract_t">Kulik TJ. Pulmonary hypertension caused by pulmonary venous hypertension. Pulm Circ 2014; 4:581.</a></li><li><a class="nounderline abstract_t">Snopek G, Pogorzelska H, Rywik TM, et al. Usefulness of endothelin-1 concentration in capillary blood in patients with mitral stenosis as a predictor of regression of pulmonary hypertension after mitral valve replacement or valvuloplasty. Am J Cardiol 2002; 90:188.</a></li><li><a class="nounderline abstract_t">Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331:961.</a></li><li><a class="nounderline abstract_t">Sagie A, Freitas N, Padial LR, et al. Doppler echocardiographic assessment of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease. J Am Coll Cardiol 1996; 28:472.</a></li><li><a class="nounderline abstract_t">Gordon SP, Douglas PS, Come PC, Manning WJ. Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up. J Am Coll Cardiol 1992; 19:968.</a></li><li><a class="nounderline abstract_t">Rinkevich D, Lessick J, Mutlak D, et al. Natural history of moderate mitral valve stenosis. Isr Med Assoc J 2003; 5:15.</a></li><li class="breakAll">WHO Technical Report Series. Rheumatic fever and rheumatic heart disease: Report of a WHO expert panel. Geneva 29 October - 1 November 2001. Geneva: WHO; 2004.</li><li><a class="nounderline abstract_t">Strasser T, Dondog N, El Kholy A, et al. The community control of rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project. Bull World Health Organ 1981; 59:285.</a></li><li><a class="nounderline abstract_t">OLESEN KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24:349.</a></li><li><a class="nounderline abstract_t">Ward C, Hancock BW. Extreme pulmonary hypertension caused by mitral valve disease. Natural history and results of surgery. Br Heart J 1975; 37:74.</a></li><li><a class="nounderline abstract_t">CASELLA L, ABELMANN WH, ELLIS LB. PATIENTS WITH MITRAL STENOSIS AND SYSTEMIC EMBOLI; HEMODYNAMIC AND CLINICAL OBSERVATIONS. Arch Intern Med 1964; 114:773.</a></li><li><a class="nounderline abstract_t">Abernathy WS, Willis PW 3rd. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin 1973; 5:131.</a></li></ol></div><div id="topicVersionRevision">Topic 8137 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553258" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Natural History of Severe Calcific Mitral Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3796056" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1936027" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13149899" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An appreciation of mitral stenosis. I. Clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4552598" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natural history of mitral stenosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14439687" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The course of mitral stenosis without surgery: ten- and twenty-year perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382606" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rheumatic fever and rheumatic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17957324" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425448" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4064266" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8483828" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rheumatic mitral stenosis. On the rise again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14879491" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390239" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Critical stenosis of aortic and mitral valves after mediastinal irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657067" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603609" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Radiation-associated valvular heart disease in Hodgkin's disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16005340" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043061" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956138" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10096934" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788227" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7754954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Percutaneous balloon mitral valvuloplasty by the Inoue technique: a multicenter study of 4832 patients in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793648" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Low-Gradient Severe Mitral Stenosis: Hemodynamic Profiles, Clinical Characteristics, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19739409" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rheumatic valvulopathies occurence, pattern and follow-up in rural area: the experience of the Shisong Hospital, Cameroon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180350" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rheumatic mitral stenosis in children: more accelerated course in sub-Saharan patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671255" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of rheumatic heart disease detected by echocardiographic screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995873" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608957" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Parachute mitral valve in adults-a systematic overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/696643" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181134" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Severe congenital mitral stenosis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108926" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Accessory mitral valve tissue: an unusual cause of congenital mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188533" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: Results from CRIC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493666" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mitral Annulus Calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13955519" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The spectrum of pure mitral stenosis. Hemodynamic studies in relation to clinical disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848223" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Two-dimensional echocardiographic diagnosis of left-atrial thrombus in rheumatic heart disease. A clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Analysis of risk factors for left atrial thrombosis in patients with rheumatic mitral stenosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054625" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24412254" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24831206" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of LA shape in predicting embolic cerebrovascular events in mitral stenosis: mechanistic insights from 3D echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152837" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25610595" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulmonary hypertension caused by pulmonary venous hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12106858" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Usefulness of endothelin-1 concentration in capillary blood in patients with mitral stenosis as a predictor of regression of pulmonary hypertension after mitral valve replacement or valvuloplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8084354" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800128" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Doppler echocardiographic assessment of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552121" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592951" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Natural history of moderate mitral valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592951" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Natural history of moderate mitral valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6972819" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The community control of rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14481743" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The natural history of 271 patients with mitral stenosis under medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1111561" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Extreme pulmonary hypertension caused by mitral valve disease. Natural history and results of surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14211590" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : PATIENTS WITH MITRAL STENOSIS AND SYSTEMIC EMBOLI; HEMODYNAMIC AND CLINICAL OBSERVATIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4780192" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Thromboembolic complications of rheumatic heart disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
